What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?

about

Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing γδ T Cells, αβ T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis.

P2860

Q55339808-B04A5294-367B-4F28-94B6-CAA9D675219D

P2860

What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?

Item

http://www.wikidata.org/entity/Q50081141

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

What is the best treatment tar ...... or α, interleukin 17, or both?

@en

What is the best treatment tar ...... or α, interleukin 17, or both?

@nl

type

Item

label

What is the best treatment tar ...... or α, interleukin 17, or both?

@en

What is the best treatment tar ...... or α, interleukin 17, or both?

@nl

prefLabel

What is the best treatment tar ...... or α, interleukin 17, or both?

@en

What is the best treatment tar ...... or α, interleukin 17, or both?

@nl

P1476

What is the best treatment tar ...... or α, interleukin 17, or both?

@en

P2093

Joachim Sieper

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perio

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability.

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

P304

1145-1150

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEX361

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Denis Poddubnyy

P577

2017-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29040753

http://www.w3.org/2001/XMLSchema#string

P921

TNF

What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?

about

P2860

P2860

What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921